Chinese drug-related stocks stumbled after a report that the Trump administration has been discussing major restrictions on medicines from the Asian nation.
The Hang Seng Biotech Index dropped as much as 8.6%, the most in five months, before paring much of the loss. A draft executive order aims to boost US output of medicines that are currently mass-produced in China, and impose tough scrutiny on licensing deals for experimental drugs, according to the New York Times report.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.